Simultan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Simultan

What is Simultan? Defining its Identity and Purpose

Property Description
Active ingredient Valsartan
Form Oral tablet or film-coated tablet
Pharmacological class Angiotensin II Receptor Blocker (ARB)
Common use Systemic blood pressure lowering
Origin Synthetic compound

What is Simultan and What Class of Medicine is It?

Simultan is a prescription-only medication whose active component is Valsartan, a substance belonging to the Angiotensin II Receptor Blocker (ARB) class of drugs. This classification identifies Simultan as a dedicated antihypertensive agent primarily used to influence the body’s cardiovascular regulation system. Valsartan is a synthetic compound, specifically a non-peptide derivative, which provides a stable and consistent therapeutic effect when administered orally. As an ARB, Valsartan functions by relaxing blood vessels so blood can flow more easily. Simultan is typically marketed and positioned for adult patients requiring long-term, once-daily management of their cardiovascular condition.


What is the Purpose of Valsartan in Simultan?

The general purpose of the active ingredient Valsartan is to facilitate blood pressure lowering by modulating a crucial pathway known as the Renin-Angiotensin-Aldosterone System (RAAS). Simultan achieves this by directly and selectively blocking the AT₁ receptor, preventing the powerful constrictive action of the chemical Angiotensin II. This selective blockade of the AT₁ receptor is a clinically recognized mechanism for controlling peripheral vascular resistance. This targeted mechanism principle allows blood vessels to relax (vasodilation) and widen, which effectively reduces the overall pressure and resistance within the circulatory system, thereby alleviating strain on the entire cardiovascular system.


What is the Composition and Form of Simultan?

Simultan is typically supplied as an oral tablet or film-coated tablet designed for systemic action, where the active substance is absorbed into the bloodstream. The product’s composition includes the active ingredient, Valsartan, combined with various pharmaceutical excipients necessary to form the solid dosage unit and ensure its stability and bioavailability. The oral route of administration and solid form are chosen characteristics to support the long-acting and consistent daily management required for cardiovascular therapy, differentiating it from formulations that require multi-day dosing or different administration routes.

Regulatory References

  1. Valsartan: MedlinePlus Drug Information

What side effects are possible with Simultan?

Possible Side Effects and Safety Information

The safety profile of Simultan (Valsartan) is formally classified based on the frequency and type of effects documented in regulatory sources such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). These effects are organized by System-Organ Class (SOC) to identify affected physiological systems.

Adverse reactions are grouped by frequency of occurrence:

  • Common (observed in ge 1/100 to <1/10 patients): Reactions often involve the nervous system, including dizziness and headache. Hypotension (low blood pressure), fatigue, and viral infection are also documented as common.
  • Uncommon (observed in ge 1/1,000 to <1/100 patients): These include syncope (fainting), vertigo, cough, and gastrointestinal disorders such as diarrhea and abdominal pain. A serious adverse reaction, angioedema (swelling of the face, lips, or throat), is also classified as uncommon.

Reactions whose frequency is Not Known from available data include hyperkalemia (elevated blood potassium) and renal function decline.

Serious Adverse Reactions highlighted in regulatory documents include angioedema and the potential for severe hypotension. Furthermore, specific safety limitations are defined for certain patient groups. Simultan is contraindicated during the second and third trimesters of pregnancy and in patients with severe hepatic impairment. Official texts note that orthostatic effects (dizziness upon standing) are more likely at treatment initiation or following a dose increase. Safety restrictions also forbid its use alongside Aliskiren in patients with diabetes or existing moderate-to-severe renal impairment.

Overdose and Emergency Response

The official regulatory profile for Simultan overdose is defined by the consequences of excessive pharmacological action, which centers on Profound Hemodynamic Instability. This instability presents primarily as Excessive Hypotension (a severe drop in blood pressure), which is documented as the chief clinical manifestation. Associated clinical signs of systemic compromise include dizziness, fainting (syncope), decreased consciousness, and changes in heart rate, such as tachycardia or bradycardia. These manifestations are documented to potentially escalate to serious, life-threatening outcomes such as circulatory shock or impaired renal function if not addressed.

Immediate action is mandatory in all suspected overdose situations. Regulatory documents explicitly state that patients must seek immediate medical attention and contact emergency services or a poison control center for severe presentations, particularly if symptoms involve collapse, seizure, trouble breathing, or inability to be awakened.

Management of a documented overdose is strictly symptomatic and supportive. Official labeling confirms that no specific antidote is known for Valsartan. In cases of profound hypotension, documented procedural steps include placing the patient in a supine position and administering an intravenous infusion of normal saline. Regulatory information also notes that the active substance is not significantly removed by hemodialysis.

Therapeutic Uses of Simultan

Simultan is commonly used to manage serious cardiovascular conditions and the symptoms related to increased systemic burden, and is commonly used as supportive treatment in these areas. The use of Simultan is commonly described across three main therapeutic domains.

The medicine is relevant when supportive symptom management is appropriate for conditions where functional stability becomes affected, such as essential high blood pressure (hypertension), chronic heart failure, and following a myocardial infarction (heart attack).

“Simultan supports the patient during difficult episodes by easing the overall symptom load related to heart failure, which helps maintain a sense of stability in the condition.”

The primary benefit is supportive relief that assists with managing chronic high blood pressure, which helps maintain a sense of stability when symptoms are more noticeable. In cases of heart failure, it helps address symptom clusters that may become intense, such as those related to symptoms of systemic imbalance. Following a heart attack, it contributes to supportive relief during the stabilization phase by easing symptoms that create noticeable physiological strain.


Quick Fact: Support for Conditions Involving Systemic Stress
Simultan is relevant for easing symptoms that create noticeable functional strain linked to conditions marked by increased physiological stress, supporting overall long-term stability.

Eligibility and Restrictions for Use

Simultan (Valsartan) use is governed by official eligibility rules based on age, physiological status, and co-existing conditions.

Eligibility Status

Adults are generally eligible for all approved uses. Pediatric use is restricted: only children aged 6 years and older may use the medicine for hypertension; use in infants and for other indications is not established or is not recommended.

Absolute Prohibitions (Contraindications)

Simultan is contraindicated and must not be used by several population groups. These include patients with a known hypersensitivity to valsartan and those with severe hepatic impairment, including biliary cirrhosis or cholestasis. Use is also strictly prohibited during the second and third trimesters of pregnancy due to documented risk of fetal injury. The medicine is also contraindicated in patients with Diabetes Mellitus or specific renal impairment who are concurrently taking Aliskiren.

Use Restrictions

Use is not recommended for women in the first trimester of pregnancy or while breastfeeding. Caution is required for patients with severe renal impairment or conditions like Primary Hyperaldosteronism.

What should I know about interactions with other medicines?

Simultan Interactions with other medicines and products

Interactions occur when a medicine's effects are changed by co-administering it with another substance, which can lead to reduced effectiveness or increased side effects. To maintain safety, patients should always inform their healthcare provider and pharmacist about all products they are taking. This includes prescription and over-the-counter medicines, herbal supplements, and vitamins.

Simultan’s interaction profile is structured around two main mechanisms: Pharmacokinetic and Pharmacodynamic interactions. Pharmacokinetic interactions involve changes to how the body absorbs, distributes, metabolizes, or eliminates the medication, potentially altering its concentration in the bloodstream. Pharmacodynamic interactions occur when two agents affect the body in similar or opposing ways, leading to additive or antagonistic effects.

Interacting Product Categories

Category Potential Interaction Type
Other CNS Depressants Pharmacodynamic (Additive Sedation)
Enzyme Modulators (CYP Inhibitors/Inducers) Pharmacokinetic (Altered Exposure)
Certain Herbal Supplements Pharmacokinetic/Pharmacodynamic (Varied Effect)

Simultan may require dose adjustment or spaced timing when taken with medicines that share a metabolic pathway or cause central nervous system (CNS) depression. Specific restrictions, such as avoiding alcohol or certain foods, may also be relevant. Always refer to the official prescribing information or consult a professional for individualized guidance on managing potential interactions.

Mechanism of Action

Simultan is an immunostimulant agent that modulates the cellular and humoral immune systems. Its action focuses on enhancing the body's immunological reactions. It promotes the activation and proliferation of key immune cells, including T lymphocytes and B lymphocytes, thereby supporting cell-mediated and antibody-mediated immunity.

At the intracellular level, Simultan influences signaling pathways that regulate immune cell function. This includes the modulation of cytokine and chemokine expression, which acts as a downstream cascade to amplify the systemic immune response. Specifically, the agent alters the balance of immune-regulatory molecules, shifting the environment toward an enhanced state of responsiveness. The system-level physiological consequence is a generalized augmentation of the immune system's readiness, involving an increase in the circulating levels of specific immune components, leading to a fortified overall immune state.

Dosage and Administration Information

How to Use Simultan: Administration Guidelines

Simultan (Valsartan) is strictly for oral administration, available as both tablets and an oral suspension. The primary distinction in use depends on the condition being addressed, which dictates the required dosing frequency and range.

Dosing Schedules and Frequency

The frequency of administration is tied directly to the therapeutic context:

  • For managing hypertension, the dosage is typically taken once daily. The standard adult starting dose is 80 mg or 160 mg, with the maximum allowed dose being 320 mg once daily.
  • For the management of chronic heart failure or following a myocardial infarction (Post-MI), the medicine must be taken twice daily. Dosing starts low (40 mg total daily for heart failure, or 20 mg twice daily for Post-MI) and is gradually increased, or titrated, toward a target maintenance dose over several weeks.

Administration Conditions and Adjustments

Simultan tablets may be taken with or without food, providing flexibility for consistent daily timing. The full blood pressure-lowering effect is typically achieved after approximately four weeks of continuous therapy.

Specific limitations exist for certain populations. The dose should not exceed 80 mg daily in adult patients with mild to moderate hepatic impairment without cholestasis. Furthermore, the dosing for pediatric patients with hypertension is based on their body weight, and the oral suspension and tablet forms are not substitutable on a milligram-for-milligram basis due to differing systemic exposure.

Recent Clinical Evidence

Simultan: Recent Clinical Evidence

Evidence for Use in High Blood Pressure (Hypertension)

Research focusing on Simultan's use in high blood pressure (hypertension) includes Randomized Controlled Trials (RCTs) and meta-analyses. These studies compare Simultan against placebo or established treatments, primarily monitoring changes in systolic and diastolic blood pressure over short-term intervals (e.g., 8–12 weeks). Long-term observational studies explored outcomes related to serious events such as stroke or heart attack in high-risk adult patients. However, evidence is limited regarding direct, head-to-head comparative data against all currently available drug classes for hypertension.


Evidence for Use in Chronic Heart Failure

Simultan was evaluated in large, international, long-term clinical trials that explored its role in chronic heart failure. These studies examined outcomes related to overall mortality and the rate of hospitalization due to acute episodes. Findings describe patterns observed in the rates of death and hospitalization when Simultan was monitored against placebo in adult patients with established, symptomatic heart failure (primarily those with reduced ejection fraction). Evidence remains less consistent for Heart Failure with Preserved Ejection Fraction (HFpEF), and data for very advanced or end-stage forms of the condition are insufficient.


Evidence for Use Following a Heart Attack (Post-Myocardial Infarction)

Research examined Simultan in adult patients who had recently experienced a heart attack and showed signs of reduced pumping action in the heart. Studies measured overall survival and composite endpoints reflecting subsequent heart attack and heart failure hospitalization during the post-event phase. Findings describe patterns observed in the context of long-term care plans for these post-MI patients. Comparative evidence is lacking regarding the use of Simultan in post-MI patients who do not exhibit signs of reduced heart function.


Research Gaps and Specific Populations

The core clinical evaluation included studies with significant follow-up durations, with major outcome trials monitoring patients for periods spanning three to six years, providing insight into long-term functional status. Research has explored outcomes in specific groups, including older adults and patients with Type 2 diabetes. However, data for certain groups, such as pediatric patients, remain insufficient. Research is ongoing in certain high-risk subgroups and exploring the use of Simultan in combination therapy.

Key Studies & References

  1. Valsartan (MedlinePlus Patient Information)
  2. Valsartan: a selective antagonist for the angiotensin AT1 receptor

Frequently Asked Questions (FAQ)

Common questions about Simultan (FAQ)

Q: How quickly should I expect to feel the effects of Simultan?

Studies indicate that the active component of Simultan is rapidly absorbed into the bloodstream, reaching its highest concentration about 1 to 4 hours after administration. However, the full therapeutic benefit of Simultan in lowering blood pressure is generally observed after about four weeks of continuous treatment.

Q: How long does one dose of Simultan typically stay active in the body?

The official prescribing information indicates that the active ingredient (Valsartan) has an elimination half-life of roughly 6 to 9 hours. This duration supports the once- or twice-daily dosing schedules that aim to maintain a consistent therapeutic effect.

Q: Does Simultan cause weight gain or weight loss?

The official product labeling does not identify weight gain or weight loss as common or uncommon adverse reactions reported in clinical trials. While these events are sometimes reported, official clinical data do not suggest that Simultan causes significant changes in body weight.

Q: Can Simultan affect sleep patterns?

Official product information notes that Simultan may cause central nervous system (CNS) effects, such as dizziness and headache. However, the label does not specifically list sleep disturbance or insomnia as a common side effect experienced by users.

Q: Does Simultan interact with common over-the-counter cold medicines?

Yes, regulatory warnings indicate that Simultan can interact with certain ingredients commonly found in OTC cold remedies. Specifically, combinations with nonsteroidal anti-inflammatory drugs (NSAIDs) or sympathomimetic agents may reduce the blood pressure-lowering effect and could potentially affect kidney function. Consultation with a healthcare provider is recommended before combining Simultan with any OTC cold remedies.

Q: Are there specific foods or beverages I should avoid while on Simultan?

The main warning relates to potassium intake. Official labeling advises against the use of potassium-containing salt substitutes and over-the-counter potassium supplements, as combining them with Simultan may lead to excessively high potassium levels in the blood (hyperkalemia).

Q: Can Simultan affect hormone levels?

Simultan works by blocking the Angiotensin II Receptor (AT1), which directly modulates the Renin-Angiotensin-Aldosterone System (RAAS). This mechanism inherently influences the concentration of several physiological hormones, most notably aldosterone, which is involved in blood pressure regulation.

Q: Can Simultan affect fertility?

Based on regulatory-backed patient information, there is no clear evidence to suggest that the active ingredient (Valsartan) reduces fertility in men or women. However, its use is strictly prohibited (contraindicated) during the second and third trimesters of pregnancy due to documented risks of fetal injury.

Q: Can children or teenagers take Simultan?

Official prescribing information confirms that Simultan is approved for treating high blood pressure (hypertension) in children and adolescents who are 6 years of age and older. Its use is not approved or recommended for children younger than 6.

Q: Can people with kidney problems use Simultan?

Dose adjustments are generally not needed for mild to moderate kidney impairment. However, use in this population is associated with a potential risk of impaired kidney function and requires careful clinical oversight, especially for patients with severe kidney problems.

Q: Is Simultan safe for people who have liver disease?

Simultan is strictly contraindicated (must not be used) in patients with severe liver impairment, including conditions like cholestasis or biliary cirrhosis. For patients with mild to moderate liver impairment that does not involve cholestasis, the prescribed dose must be reduced.

Q: Is there a risk of becoming dependent on Simultan?

The active ingredient in Simultan (Valsartan) is not classified as a controlled substance by regulatory bodies. Furthermore, its official product labeling does not contain any warnings regarding dependence or addiction potential.

Q: Is it important to take Simultan at the exact same time every day?

Simultan is intended for consistent, long-term daily management of a chronic condition, and official prescribing guidelines emphasize the importance of consistent daily administration. Studies suggest that the timing of administration (e.g., morning vs. evening) can influence the effectiveness of blood pressure control throughout a 24-hour period.

Q: How often do follow-up blood tests or checks need to happen while on Simultan?

Regulatory guidance indicates the need for follow-up monitoring of blood potassium levels and kidney function (creatinine). This monitoring is particularly advised for patients with existing heart conditions, kidney problems, or those using other medications that can also affect potassium levels.

Q: Does Simultan have a black box warning?

Yes, Simultan's labeling includes an FDA Boxed Warning (often called a Black Box Warning). This warning alerts users and prescribers that the drug can cause severe injury and death to a developing fetus if taken during the second or third trimesters of pregnancy.

Q: Is Simultan generally considered a well-tolerated drug?

Regulatory assessments of clinical trial data often conclude that the drug is generally considered well-tolerated compared to some older classes of blood pressure medication. While side effects are reported, they are typically described as mild and manageable.

How should Simultan be stored and disposed of?

How to Store and Dispose of Simultan (Valsartan)

Simultan tablets must be stored at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C). The medicine must be protected from moisture and freezing and should not be stored above 86 F (30 C).

Packaging and Protection

For stability, keep the medicine in the original container, ensuring it is kept tightly closed. Storage must be in a location that is out of the sight and reach of children to prevent accidental ingestion.

Disposal

Do not dispose of unused or expired Simultan in household trash or down the drain (wastewater). Consult a pharmacist or local regulatory body for the proper procedures regarding the disposal of unused medications as pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Simultan found in:

A-Z Index: